SCHEMBL21752181

SCHEMBL21752181

OCc1cc2ncc(Br)cn2n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.51
ALDH1A1 P00352 4/20 0.51
GAA P10253 1/20 0.51
MAPT P10636 1/20 0.51
ESR2 Q92731 5/20 0.49
HPGD P15428 1/20 0.49
TSHR P16473 1/20 0.49
RECQL P46063 1/20 0.47
GRM5 P41594 8/20 0.44
POLB P06746 5/20 0.44
KDM4E B2RXH2 4/20 0.44
RAB9A P51151 3/20 0.44
APOBEC3A P31941 2/20 0.44
HSD17B10 Q99714 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
APOBEC3G Q9HC16 1/20 0.44
NR4A1 P22736 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ESR1 P03372 3/20 0.42
CTDSP1 Q9GZU7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18555346 0.84 TDP1 (0.48) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL24967785 0.79 GRM5 (0.44) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL5070925 0.76 KDM4E (0.49) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL24966569 0.75 LMNA (0.38) TDP1ALDH1A1GAAMAPTHPGD
SCHEMBL22027717 0.74 TDP1 (0.47) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL18555435 0.74 TDP1 (0.47) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL974117 0.74 RAB9A (0.56) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL21355505 0.73 KLKB1 (0.40) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL1011158 0.72 TDP1 (0.63) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL1988889 0.71 TDP1 (0.48) TDP1ALDH1A1GAAMAPTESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3841086-B1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS ACHILLION PHARMACEUTICALS INC (US) 2025-04-23 EP disclosed
US-20230022157-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2023-01-26 US disclosed
EP-3841086-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS Achillion Pharmaceuticals, Inc. (US) 2021-06-30 EP disclosed
WO-2020041301-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2020-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230022157-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS CFD, CFH, TFPI TDP1 4292/4885ALDH1A1 4494/4885GAA 2328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.